Glaukos Completes Patient Enrollment in Phase II Clinical Trial for iDose™ Travoprost Intraocular Implant in Glaucoma Patients
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced the completion of patient enrollment in the U.S. Investigational New Drug (IND) Phase II study of its Travoprost Intraocular Implant with the iDose™ delivery system in patients with glaucoma. Implanted during a micro-invasive proce